These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 33877856

  • 1. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
    Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ.
    J Clin Oncol; 2021 Jun 10; 39(17):1888-1898. PubMed ID: 33877856
    [Abstract] [Full Text] [Related]

  • 2. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
    Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S.
    Blood; 2021 Dec 02; 138(22):2278-2289. PubMed ID: 34265047
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Belumosudil for chronic graft-versus-host disease.
    Taylor B, Cohen J, Tejeda J, Wang TP.
    Drugs Today (Barc); 2022 May 02; 58(5):203-212. PubMed ID: 35535812
    [Abstract] [Full Text] [Related]

  • 5. Belumosudil: First Approval.
    Blair HA.
    Drugs; 2021 Sep 02; 81(14):1677-1682. PubMed ID: 34463931
    [Abstract] [Full Text] [Related]

  • 6. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.
    Zanin-Zhorov A, Blazar BR.
    Clin Immunol; 2021 Sep 02; 230():108823. PubMed ID: 34400321
    [Abstract] [Full Text] [Related]

  • 7. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
    Salhotra A, Sandhu K, O'Hearn J, Ali H, Nakamura R, Modi BG.
    Expert Rev Clin Immunol; 2023 Mar 02; 19(3):241-251. PubMed ID: 36440483
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
    Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR.
    Blood; 2016 Apr 28; 127(17):2144-54. PubMed ID: 26983850
    [Abstract] [Full Text] [Related]

  • 11. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies.
    Lee SJ, Cutler C, Blazar BR, Tu A, Yang Z, Pavletic SZ.
    Transplant Cell Ther; 2022 Oct 28; 28(10):700.e1-700.e6. PubMed ID: 35781099
    [Abstract] [Full Text] [Related]

  • 12. FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy.
    Przepiorka D, Le RQ, Ionan A, Li RJ, Wang YH, Gudi R, Mitra S, Vallejo J, Okusanya OO, Ma L, Yang Y, Patel P, Mezaache D, Shah R, Banerjee A, McLamore S, Maung AN, Goldberg KB, Pazdur R, Theoret MR, De Claro RA.
    Clin Cancer Res; 2022 Jun 13; 28(12):2488-2492. PubMed ID: 35135839
    [Abstract] [Full Text] [Related]

  • 13. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.
    Ali F, Ilyas A.
    Curr Res Transl Med; 2022 Jul 13; 70(3):103343. PubMed ID: 35339032
    [Abstract] [Full Text] [Related]

  • 14. Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study.
    Chen T, Li J, Wei X, Yao H, Zhu L, Liu J, Liu Y, Wang P, Feng Y, Gao S, Liu H, Wang L, Zhao L, Gao L, Zhang C, Gao L, Zhang X, Kong P.
    Acta Haematol; 2024 Jul 13; 147(5):499-510. PubMed ID: 38232716
    [Abstract] [Full Text] [Related]

  • 15. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A.
    Biol Blood Marrow Transplant; 2015 Sep 13; 21(9):1576-82. PubMed ID: 25985915
    [Abstract] [Full Text] [Related]

  • 16. Crystal structure of the Rho-associated coiled-coil kinase 2 inhibitor belumosudil bound to CK2α.
    Brear P, Hyvönen M.
    Acta Crystallogr F Struct Biol Commun; 2022 Oct 01; 78(Pt 10):348-353. PubMed ID: 36189718
    [Abstract] [Full Text] [Related]

  • 17. Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States.
    Bachier CR, Skaar JR, Dehipawala S, Miao B, Ieyoub J, Taitel H.
    J Med Econ; 2022 Oct 01; 25(1):857-863. PubMed ID: 35674411
    [Abstract] [Full Text] [Related]

  • 18. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, Sawa M, Ishikawa T, Ueda Y, Yoshinari N, Nakahara S.
    Transplant Cell Ther; 2021 Oct 01; 27(10):867.e1-867.e9. PubMed ID: 34102349
    [Abstract] [Full Text] [Related]

  • 19. Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14 C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study.
    Schueller O, Skucas E, Regev G, Shaw I, Singh N, Sanghvi M, Croft M, Lohmer L, Alabanza A, Patel J.
    Clin Pharmacol Drug Dev; 2022 Jul 01; 11(7):786-794. PubMed ID: 35231159
    [Abstract] [Full Text] [Related]

  • 20. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X, Lin Z, Wu D, Xu Y.
    Front Immunol; 2021 Jul 01; 12():673636. PubMed ID: 34276662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.